Neuromodulation of Brain Function in Alzheimer's Disease and Related Dementias
概览
- 阶段
- 早期 1 期
- 干预措施
- Active rTMS
- 疾病 / 适应症
- Alzheimer Disease
- 发起方
- Massachusetts General Hospital
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Changes in Brain Network Connectivity
- 状态
- 招募中
- 最后更新
- 2个月前
概览
简要总结
In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI).
This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI).
Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.
研究者
Alexandra Touroutoglou
Assistant Professor of Neurology
Harvard Medical School (HMS and HSDM)
入排标准
入选标准
- •Between the ages of 40-99
- •Native English speakers
- •Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points
- •Patients with PPA will be asked to bring a study partner to all visits
- •Patients with very mild or mild PPA, patients with amnestic mild cognitive impairment and cognitively unimpaired participants with preclinical AD will be included.
排除标准
- •History of head trauma involving loss of consciousness or alteration in consciousness
- •Another major neurologic or psychiatric condition
- •Known presence of a structural brain lesion (e.g. tumor, cortical infarct)
- •Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
- •Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
- •Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.
- •Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging
- •History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).
- •Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.
- •Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.
研究组 & 干预措施
AD, aMCI, lvPPA patients, and preclinical AD
All participants will receive the same study interventions in a within-subject crossover design.
干预措施: Active rTMS
AD, aMCI, lvPPA patients, and preclinical AD
All participants will receive the same study interventions in a within-subject crossover design.
干预措施: Sham rTMS
结局指标
主要结局
Changes in Brain Network Connectivity
时间窗: Baseline and post-treatment Day 11
This will include observed changes in resting-state functional connectivity as a result of the stimulation.
Changes in Memory
时间窗: Baseline and post-treatment Day 11
This will include observed changes in memory as a result of the stimulation through neuropsychological testing.